HRT and GLP-1: What Women Need to Know About Combining These Therapies

Why Clinicians Are Prescribing HRT and GLP-1 Drugs Together

Perimenopausal and postmenopausal women face a dual metabolic challenge. Declining estrogen shifts fat storage from subcutaneous depots to visceral ones, raises fasting insulin, and increases cardiovascular risk independent of caloric intake [1]. At the same time, obesity and metabolic syndrome are themselves associated with worse vasomotor symptoms and a harder transition through menopause [2]. GLP-1 receptor agonists target the metabolic side; HRT targets the hormonal side. Neither therapy fully corrects what the other addresses.

STEP-1 (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [3]. The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg achieved 20.9% weight reduction at 72 weeks [4]. Neither trial stratified by menopausal status or concurrent HRT use, which is a gap in the literature this article addresses with a proposed clinical framework below.

Estrogen does not produce weight loss on its own, but it does change body composition. A randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism found that transdermal 17-beta-estradiol reduced visceral fat area by approximately 6.8% versus placebo over 12 months in postmenopausal women with central adiposity [5]. That shift in fat distribution matters because visceral fat drives insulin resistance, which in turn blunts the appetite-suppressing signal from endogenous GLP-1 [6].

Combining the two therapies is therefore rational. The estrogen addresses fat distribution and insulin sensitivity; the GLP-1 agonist generates the caloric deficit and reduces appetite. Clinical experience at several menopause specialty centers supports this combination, though head-to-head randomized trials of HRT-plus-GLP-1 versus either agent alone have not yet been published as of mid-2025.

How Estrogen Interacts With GLP-1 Receptor Signaling

Estrogen receptors are expressed in the hypothalamic arcuate nucleus alongside GLP-1 receptors, and animal data suggest these two systems modulate each other [7]. In ovariectomized rodent models, estrogen replacement restored hypothalamic GLP-1 receptor density to levels seen in intact animals [8]. The clinical translation is not yet fully established, but the mechanistic overlap is plausible.

Gastric emptying is the more immediately relevant pharmacokinetic concern. GLP-1 agonists slow gastric motility, which reduces and delays the absorption of oral medications [9]. For women taking oral conjugated equine estrogen (CEE) or oral 17-beta-estradiol, this could reduce peak plasma estrogen concentrations and blunt therapeutic effect. The FDA labeling for semaglutide (Ozempic/Wegovy) notes this interaction and recommends monitoring for reduced oral drug efficacy [10].

Transdermal estradiol bypasses the gut entirely. A patch, gel, or spray delivers estrogen directly into the bloodstream, making it unaffected by delayed gastric emptying [11]. For women starting a GLP-1 agonist while already on oral HRT, switching to a transdermal formulation is a reasonable step. The Endocrine Society's 2023 menopause position statement also notes that transdermal estradiol carries a lower venous thromboembolism (VTE) risk than oral formulations, which is an independent reason to prefer it in women with elevated cardiovascular risk [12].

HRT Regimens by Clinical Situation

Women in Perimenopause

Perimenopause spans roughly 4 to 8 years and is defined by irregular cycles plus a rise in follicle-stimulating hormone (FSH) above 25 IU/L on at least two measurements [13]. Estrogen levels during this phase are erratic, swinging from supraphysiologic to low within a single cycle. Adding exogenous estrogen smooths those fluctuations and reduces vasomotor symptom burden.

The standard approach is low-dose cyclical HRT: transdermal estradiol 0.05 mg/day with micronized progesterone 200 mg for 12 days per cycle if the uterus is intact [14]. This regimen preserves a withdrawal bleed, which serves as a rough indicator that the endometrium is being protected. The North American Menopause Society (NAMS) 2022 position statement states that "hormone therapy remains the most effective treatment for vasomotor symptoms and is appropriate for healthy women who are within 10 years of menopause onset or younger than 60 years" [15].

For a perimenopausal woman also starting semaglutide or tirzepatide, the GLP-1 drug should be titrated to its maintenance dose before drawing conclusions about symptom control. GLP-1-induced nausea can mimic estrogen-related nausea in the first 8 to 12 weeks, making it hard to attribute symptoms accurately. Starting one therapy at a time, spaced 4 to 6 weeks apart, allows cleaner attribution of side effects.

Women in perimenopause who are taking a GLP-1 agonist and still have menstrual cycles should be counseled that GLP-1-induced rapid weight loss can occasionally disrupt cycle regularity independently of menopausal transition, though the mechanism is not fully characterized [16].

Women in Late Postmenopause

Late postmenopause is generally defined as more than 10 years after the final menstrual period. The "timing hypothesis" (also called the "window of opportunity") holds that HRT initiated more than 10 years after menopause may not reduce and could increase cardiovascular risk in some women [17]. The Women's Health Initiative (WHI) Memory Study showed that women aged 65 to 79 starting CEE plus medroxyprogesterone acetate had a higher incidence of dementia versus placebo [18].

That does not mean HRT is uniformly contraindicated in late postmenopause. It means the risk-benefit calculation changes. Women who have severe genitourinary syndrome of menopause (GSM), which includes vaginal atrophy and recurrent urinary tract infections, may still benefit from low-dose local vaginal estradiol, which produces negligible systemic absorption [19]. The FDA-approved vaginal estradiol tablets (Vagifem 10 mcg) and estradiol cream formulations are appropriate options and do not require concomitant progestogen [20].

For systemic HRT in late postmenopause, the decision should be individualized. A woman aged 62 who experienced menopause at 58 and is starting HRT is still within the timing window. A woman aged 68 who experienced menopause at 52 is 16 years out and carries higher risk. GLP-1 agonists do not alter this risk calculus, but they do address the visceral adiposity and insulin resistance that compound cardiovascular risk in late postmenopause.

HRT After Hysterectomy

Women who have had a hysterectomy (removal of the uterus) do not require progestogen. The sole indication for progestogen in HRT is endometrial protection, and no uterus means no endometrium to protect [21]. Estrogen-only HRT is therefore appropriate and preferred in this population.

The WHI estrogen-only trial (N=10,739, CEE 0.625 mg/day, women with prior hysterectomy) showed no significant increase in breast cancer risk at 7.1 years (hazard ratio 0.77 to 95% CI 0.59-1.01) [22]. This finding is meaningfully different from the combined estrogen-progestogen arm, which did show a breast cancer signal. For women who had a hysterectomy and are considering HRT plus a GLP-1 agonist, the estrogen-only regimen is safer and simpler.

Transdermal estradiol 0.05 to 0.1 mg/day is the most common starting dose. Post-hysterectomy women on GLP-1 drugs can use the patch or gel without any pharmacokinetic interference.

HRT With Uterus Intact

Any systemic estrogen given to a woman with a uterus must be paired with adequate progestogen to prevent endometrial hyperplasia and carcinoma [23]. The two main progestogen options are:

Micronized progesterone (Prometrium) 200 mg/day for 12 days per cycle in sequential regimens, or 100 mg/day continuously in postmenopausal women. Micronized progesterone has a more favorable cardiovascular and breast-safety profile than synthetic progestins like medroxyprogesterone acetate, based on data from the French E3N cohort study (N=80,377) [24].

Levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena 52 mg) delivers progestogen locally to the endometrium with minimal systemic absorption and is a guideline-recognized option for endometrial protection in women on systemic estrogen [25].

GLP-1 agonists do not interact with progesterone pharmacokinetically because oral micronized progesterone undergoes first-pass hepatic metabolism rather than relying on intestinal peak absorption in the same time-sensitive way as some other oral drugs. Still, if gastric emptying is severely delayed, some clinicians prefer vaginal micronized progesterone as an alternative route.

Any unscheduled uterine bleeding in a woman on combined HRT must be evaluated with transvaginal ultrasound and, if endometrial stripe exceeds 4 mm, with endometrial biopsy [26].

The Metabolic Case: Why GLP-1 Drugs Fill a Gap That HRT Cannot

HRT corrects the hormonal deficit. It does not generate a caloric deficit. Women who gain 10 to 15 pounds in perimenopause due to reduced physical activity, increased caloric intake, and sleep disruption will not lose that weight from estrogen alone [27]. A 2023 meta-analysis in Menopause (N=19 RCTs, 3,422 women) found that HRT produced a mean reduction in body weight of 1.1 kg versus placebo, with most of the effect attributable to redistribution of fat rather than total mass loss [28].

GLP-1 agonists, by contrast, reduce appetite through hypothalamic GLP-1 receptor activation, delay gastric emptying to prolong satiety, and modestly increase energy expenditure [29]. In women with obesity and metabolic syndrome, tirzepatide 15 mg reduced fasting insulin by 55% and HbA1c by 2.1 percentage points in SURMOUNT-1 [4]. These metabolic improvements directly address the insulin resistance that worsens vasomotor symptoms and accelerates visceral fat accumulation in the postmenopausal years [30].

HealthRX Clinical Decision Framework: Sequencing HRT and GLP-1 Therapy

The following protocol reflects current evidence and the clinical judgment of the HealthRX medical team. It is not a substitute for individual patient evaluation.

| Clinical Scenario | Recommended HRT Regimen | GLP-1 Start Timing | Monitoring Priority | |---|---|---|---| | Perimenopause, BMI 27-35, vasomotor symptoms | Transdermal E2 0.05 mg + micronized P4 200 mg x 12d/cycle | 4-6 weeks after HRT stabilized | Cycle regularity, nausea overlap | | Postmenopause, BMI >30, no uterus | Transdermal E2 0.05-0.1 mg/day (estrogen only) | Can start concurrently | Lipids, blood pressure at 12 weeks | | Postmenopause, uterus intact, BMI >30 | Transdermal E2 + continuous micronized P4 100 mg/day | 4-6 weeks after HRT stabilized | Endometrial stripe if breakthrough bleeding | | Late postmenopause (>10 yr), GSM only | Vaginal estradiol 10 mcg tablet x 2/week | Can start concurrently | VTE symptoms, blood pressure | | Post-hysterectomy, any BMI >27 | Transdermal E2 0.05-0.1 mg/day (estrogen only) | Can start concurrently | Estradiol levels at 8 weeks |

Cardiovascular Risk: Reading the Evidence Correctly

The WHI (1991-2004) alarmed clinicians and patients with its finding of increased cardiovascular events in the combined HRT arm [31]. However, the average age of WHI enrollees was 63, many were more than 10 years past menopause, and a substantial proportion had pre-existing cardiovascular risk factors. The Kronos Early Estrogen Prevention Study (KEEPS, N=727) enrolled women within 36 months of their final menstrual period and found no increase in carotid intima-media thickness or coronary artery calcium scores versus placebo at 4 years [32].

The ELITE trial (N=643) divided postmenopausal women into early (less than 6 years since menopause) and late (more than 10 years since menopause) groups. Oral 17-beta-estradiol slowed carotid intima-media thickness progression in the early group but not in the late group [33]. This is the clearest RCT evidence for the timing window.

GLP-1 agonists independently reduce cardiovascular risk. The LEADER trial (N=9,340) showed liraglutide 1.8 mg reduced major adverse cardiovascular events (MACE) by 13% versus placebo in adults with type 2 diabetes and high cardiovascular risk (HR 0.87 to 95% CI 0.78-0.97, P<0.001 for superiority) [34]. SUSTAIN-6 (N=3,297) showed semaglutide 0.5-1 mg reduced MACE by 26% (HR 0.74 to 95% CI 0.58-0.95) [35]. These trials included predominantly male populations; cardiovascular outcomes data specific to postmenopausal women on GLP-1 drugs remain an active research area.

Used together in appropriately selected women, HRT (started within the timing window) and a GLP-1 agonist may offer additive cardiovascular protection through complementary mechanisms: estrogen via favorable lipid effects and vascular function, GLP-1 agonists via blood pressure reduction, weight loss, and direct cardiac effects [36].

Bone Health: An Underappreciated Benefit of HRT

Postmenopausal women lose approximately 1 to 2% of bone mineral density (BMD) per year in the first 5 years after menopause, accelerating to 2 to 3% in some women [37]. Estrogen deficiency drives osteoclast activity. HRT is the only therapy that simultaneously treats vasomotor symptoms and preserves bone. The NAMS 2022 position statement notes that "hormone therapy is the only FDA-approved treatment that addresses both menopausal symptoms and fracture prevention simultaneously" [15].

Rapid weight loss from GLP-1 agonists may slightly reduce BMD, particularly at the hip. A 2023 analysis of semaglutide trials found that 68 weeks of semaglutide 2.4 mg was associated with a 0.5% reduction in hip BMD compared to 0.1% with placebo [38]. The mechanism may involve reduced mechanical loading as body weight drops. For postmenopausal women already at risk for osteoporosis (T-score <-1.0 on DEXA), adding HRT to a GLP-1 regimen may partially offset this bone loss concern.

Women with T-score below -2.5 (osteoporosis) on DEXA who also need weight loss should discuss the HRT-plus-GLP-1 combination with a clinician, with annual DEXA monitoring and adequate calcium (1 to 200 mg/day) and vitamin D3 (1,500-2 to 000 IU/day) supplementation [39].

Practical Prescribing Considerations

Starting doses for HRT in the context of GLP-1 use: Transdermal estradiol patch: 0.0375 to 0.05 mg/day, changed twice weekly. Gel: 0.75 mg/day (one pump), titrated to symptom response and estradiol level (target 40-100 pg/mL in postmenopause, 50-150 pg/mL in perimenopause). Spray: one to three sprays daily to the inner forearm.

Starting doses for GLP-1 agonists: Semaglutide (Wegovy): 0.25 mg subcutaneously once weekly, increased every 4 weeks to a target of 2.4 mg. Tirzepatide (Zepbound): 2.5 mg subcutaneously once weekly, increased every 4 weeks to a target of 10 to 15 mg [40].

Lab monitoring at baseline and follow-up: Estradiol, FSH, fasting glucose, HbA1c, lipid panel, liver enzymes, and thyroid-stimulating hormone at baseline. Repeat estradiol and FSH at 8 weeks after HRT initiation. Repeat fasting glucose and lipids at 12 weeks after GLP-1 initiation. DEXA scan if not done within 2 years in women aged 60 or older, or earlier in women with fracture risk factors [41].

Contraindications to systemic HRT (regardless of GLP-1 use): active or recent arterial thromboembolic disease, unexplained uterine bleeding, known or suspected hormone-sensitive malignancy, active liver disease, and personal history of VTE without anticoagulation [42].

Semaglutide and tirzepatide are contraindicated in women with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 [10].